Baricitinib 2 mg for the treatment of atopic dermatitis in <scp>North America</scp> : Long‐term efficacy and patient‐reported outcomes-Reference-Cited by-同舟云学术

Baricitinib 2 mg for the treatment of atopic dermatitis in North America : Long‐term efficacy and patient‐reported outcomes

Published:2022-11-04 Issue:12 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Simpson Eric¹,Armstrong April²,Boguniewicz Mark³,Chiesa Fuxench Zelma C.⁴,Feely Meghan⁵⁶,Pierce Evangeline⁵,Sun Luna⁵,Chen Yun‐Fei⁵,Angle Robinette⁵,Silverberg Jonathan I.⁷

Affiliation:

1. Department of Dermatology Oregon Health and Science University Portland Oregon USA

2. Department of Dermatology, Keck School of Medicine University of Southern California Los Angeles California USA

3. Division of Allergy‐Immunology, Department of Pediatrics National Jewish Health and University of Colorado School of Medicine Denver Colorado USA

4. Department of Dermatology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

5. Eli Lilly and Company Indianapolis Indiana USA

6. Department of Dermatology Mount Sinai Health System New York New York USA

7. Department of Dermatology George Washington University School of Medicine and Health Sciences Washington DC USA

Funder

Eli Lilly and Company

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15954

Reference24 articles.

1. Atopic Dermatitis

2. Comorbidity in Atopic Dermatitis

3. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth

4. AbbeA Falissard B Gadkari A Wei W Arnold R Eckert L.Atopic dermatitis from the patient's perspective: insights from text‐mining analysis of a cross‐sectional study in US adults. Poster presented at: 75th Annual Meeting of American Academy of Dermatology; March 3–7 2017; Orlando FL.https://www.aad.org/eposters/view/Abstract.aspx?id=4781

5. Impact of disease severity on sleep quality in Japanese patients with atopic dermatitis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2);American Journal of Clinical Dermatology;2024-03-25

2. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs;Allergy;2024-01-08